C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 6.83 HKD -2.01% Market Closed
Market Cap: 2.2B HKD
Have any thoughts about
Cutia Therapeutics?
Write Note

Cutia Therapeutics
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cutia Therapeutics
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
C
Cutia Therapeutics
HKEX:2487
Total Receivables
ÂĄ77m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Receivables
ÂĄ3.2B
CAGR 3-Years
77%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Receivables
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
48%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Receivables
ÂĄ3.1B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Receivables
ÂĄ25.5B
CAGR 3-Years
34%
CAGR 5-Years
41%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Total Receivables
ÂĄ230.8m
CAGR 3-Years
72%
CAGR 5-Years
75%
CAGR 10-Years
N/A
No Stocks Found

Cutia Therapeutics
Glance View

Market Cap
2.1B HKD
Industry
Biotechnology

Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.

Intrinsic Value
11.5 HKD
Undervaluation 41%
Intrinsic Value
Price
C

See Also

What is Cutia Therapeutics's Total Receivables?
Total Receivables
77m CNY

Based on the financial report for Dec 31, 2023, Cutia Therapeutics's Total Receivables amounts to 77m CNY.

What is Cutia Therapeutics's Total Receivables growth rate?
Total Receivables CAGR 1Y
1 777%

Over the last year, the Total Receivables growth was 1 777%.

Back to Top